Quotient Company Profile (NASDAQ:QTNT)

Analyst Ratings

Consensus Ratings for Quotient (NASDAQ:QTNT) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.00 (382.76% upside)

Analysts' Ratings History for Quotient (NASDAQ:QTNT)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016Jefferies GroupReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/21/2015Robert W. BairdDowngradeOutperform -> Neutral$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Quotient (NASDAQ:QTNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
5/23/2016Q4($0.59)($0.41)$5.05 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/8/2016Q316($0.76)($0.48)$4.06 million$4.35 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2015Q216($0.80)($0.25)$4.42 million$4.27 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q116($0.67)($0.60)$4.90 million$4.85 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/18/2015Q415($0.52)($0.77)$4.36 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2015($0.68)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014($0.58)($0.82)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Quotient (NASDAQ:QTNT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.69)($0.58)($0.64)
Q2 20161($0.54)($0.54)($0.54)
Q3 20162($0.50)($0.46)($0.48)
Q4 20161($0.63)($0.63)($0.63)
Q1 20171($0.71)($0.71)($0.71)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.38)($0.38)($0.38)
Q4 20171($0.42)($0.42)($0.42)
Q1 20181($0.03)($0.03)($0.03)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.26)($0.26)($0.26)
Q4 20181$0.25$0.25$0.25
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Quotient (NASDAQ:QTNT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Quotient (NASDAQ:QTNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/9/2016Jeremy StackawitzPresidentSell15,000$10.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Stephen UngerCFOSell14,484$9.99$144,695.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2016Stephen UngerCFOSell8,516$10.49$89,332.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2016Zubeen ShroffDirectorBuy222,222$9.00$1,999,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Sarah A OconnorDirectorBuy10,000$15.50$155,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Stephen UngerInsiderBuy3,000$15.00$45,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2015Jeremy StackawitzPresidentSell30,000$16.80$504,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Jeremy StackawitzPresidentSell4,012$16.88$67,722.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Jeremy StackawitzPresidentSell14,140$17.00$240,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014Galen Partners V LpMajor ShareholderBuy157,895$9.50$1,500,002.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Stephen UngerCFOBuy3,000$9.13$27,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2014Galen Partners V LpMajor ShareholderBuy312,500$8.00$2,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Quotient (NASDAQ:QTNT)
DateHeadline
07/29/16 06:11 PMQuotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
07/29/16 08:44 AMQuotient Prices 2.8 Million Ordinary Shares -
06/23/16 07:43 AMShould You Get Rid of Quotient Limited (QTNT) Now? -
06/04/16 08:58 AMQuotient Ltd (QTNT.OQ)
05/31/16 07:30 AMQuotient Limited to Participate in Jefferies 2016 Global Healthcare Conference - [GlobeNewswire] - JERSEY, Channel Islands, May 31, 2016-- Quotient Limited, a commercial-stage diagnostics company, today announced that the company’ s Chairman& CEO, Paul Cowan, will present at the Jefferies 2016 Global ...
05/31/16 05:38 AMQUOTIENT LTD Files SEC form 10-K, Annual Report -
02/26/16 09:19 AMQuotient (QTNT) Is in Oversold Territory: What's Next? -
02/17/16 10:06 AMQuotient (QTNT) Sees Hammer Chart Pattern: Time to Buy? -
02/16/16 01:02 PMQuotient Ltd. Earnings Analysis: Q3, 2016 By the Numbers -
02/09/16 03:57 PMQUOTIENT LTD Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
02/08/16 08:29 AMEdited Transcript of QTNT earnings conference call or presentation 8-Feb-16 1:30pm GMT -
02/08/16 06:59 AMQuotient reports 3Q loss -
02/08/16 06:45 AMQuotient Limited Reports Third Quarter Fiscal 2016 Financial Results - [GlobeNewswire] - Considerable progress on development and commercial scale-up of MosaiQ™, Quotient’ s next-generation automation platform for transfusion diagnostics Marketing of MosaiQ™ expected to start in the fourth ...
02/05/16 04:38 PMTrader: Quotient's Public Offering Is 'Priced To Work,' Notes Stock could See Upside - Shares of Quotient Ltd (NASDAQ: QTNT) plunged more than 25 percent on Friday and hit a new 52-week low of $7.47 after the company announced the pricing of a public offering of 4.44 million shares at a price ...Full story available on Benzinga.com
02/05/16 07:40 AMQuotient Gears Up for Secondary Offering -
02/05/16 01:57 AM2:57 am Quotient prices 4,444,445 of ordinary shares at $9.00 per share. -
02/03/16 03:11 PMQUOTIENT LTD Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
02/03/16 03:01 PMQuotient Limited Announces Proposed Underwritten Offering of Ordinary Shares - [GlobeNewswire] - JERSEY, Channel Islands, Feb. 03, 2016-- Quotient Limited, a commercial-stage diagnostics company, today announced that it intends to commence an underwritten public offering of $40 million of its ordinary ...
02/01/16 07:00 AMQuotient Limited to Report Third Quarter Fiscal 2016 Financial Results and Host Conference Call - [GlobeNewswire] - JERSEY, Channel Islands, Feb. 01, 2016-- Quotient Limited, a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ending December 31, 2015 will be released ...
01/11/16 06:01 AMQuotient Limited Announces Positive Serological Disease Screening Results and Provides MosaiQ™ Development Program Update - [GlobeNewswire] - JERSEY, Channel Islands, Jan. 11, 2016-- Quotient Limited, a commercial-stage diagnostics company, will present the following update on the MosaiQ™ development program during its company presentation at ...
01/11/16 06:00 AMQuotient Limited to Expand Capability of Its MosaiQ™ Next-Generation Transfusion Diagnostics Platform to Include Nucleic Acid Testing - [GlobeNewswire] - Initial feasibility study demonstrates ability to detect nucleic acid using MosaiQ TM Potential for a single unified platform to perform blood grouping along with serological and molecular disease screening ...
12/22/15 01:01 PMQuotient Limited to Participate in J.P. Morgan 2016 Healthcare Conference - [GlobeNewswire] - JERSEY, Channel Islands, Dec. 22, 2015-- Quotient Limited, a commercial-stage diagnostics company, today announced that the company’ s Chairman and Chief Executive Officer Paul Cowan will present at the ...
12/22/15 10:48 AMQuotient Ltd. Earnings Analysis: Q2, 2016 By the Numbers -
12/09/15 03:45 PMQUOTIENT LTD Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events -
12/09/15 03:31 PMQuotient Limited Announces Plans for New Product Development and Manufacturing Facility Near Edinburgh, Scotland - [GlobeNewswire] - JERSEY, Channel Islands -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it has entered into a construction contract with MW High Tech Projects UK Limited ...
12/08/15 12:17 PMQUOTIENT LTD Financials -
11/23/15 09:19 AMQuotient Limited (Nasdaq: QTNT) to Ring The Nasdaq Stock Market Closing Bell - [at noodls] - ADVISORY, Nov. 23, 2015 (GLOBE NEWSWIRE) -- What: Quotient Limited (Nasdaq:QTNT), a commercial-stage transfusion diagnostics company, will visit the Nasdaq MarketSite in Times Square to celebrate its one ...
11/23/15 07:00 AMQuotient Limited to Ring the NASDAQ Stock Market Closing Bell - [GlobeNewswire] - JERSEY, Channel Islands -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company's Chairman and Chief Executive Officer Paul Cowan will ring the closing ...
11/10/15 03:06 PMQuotient Limited to Participate in Canaccord Genuity Medical Technology & Diagnostics Forum - [GlobeNewswire] - JERSEY, Channel Islands -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company's Chief Financial Officer, Stephen Unger, will present at the Canaccord ...
11/04/15 05:34 PMQUOTIENT LTD Files SEC form 10-Q, Quarterly Report -

Social

About Quotient

Quotient logoQuotient Limited is a commercial-stage diagnostics company. The Company is focused on blood grouping and serological disease screening. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood, which includes antigen typing and antibody identification. Serological disease screening involves the screening of donor blood for unwanted pathogens. The Company is engaged in the development, manufacturing and commercialization of conventional reagent products for blood grouping. The Company also undertakes product development projects for its original equipment manufacturer (OEM) customers. The Company develops, manufactures and commercializes the products including Antisera products, Reagent Red Blood Cells, Whole Blood Controls and Ancillary products. The Company is developing MosaiQ to characterize donor and patient blood, and serologically screen donor blood for specific viruses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: QTNT
  • CUSIP:
Key Metrics:
  • Previous Close: $7.50
  • 50 Day Moving Average: $8.08
  • 200 Day Moving Average: $9.30
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $83.38M
  • Beta: 1.7
  • Current Year EPS Consensus Estimate: $-2.07 EPS
  • Next Year EPS Consensus Estimate: $-0.34 EPS
Additional Links:
Quotient (NASDAQ:QTNT) Chart for Saturday, July, 30, 2016